

**Table 2.2. Summary of results from four studies of combined estrogen–progestogen oral contraceptives and breast cancer in carriers of *BRCA1* and *BRCA2* mutations**

Reference	Feature of use	[Cases/controls or person years] OR/HR (95% CI)			
		<i>BRCA1</i> mutation carriers		<i>BRCA2</i> mutation carriers	
Ever use of oral contraceptives					
Narod et al. (2002)	Never	NG	1.00 (reference)	NG	1.00 (reference)
	Ever		1.20 (1.02–1.40)	NG	0.94 (0.72–1.24)
Gronwald et al. (2006)	Never	[292/285]	1.0 (reference)	—	—
	Ever	[56/63]	0.8 (0.5–1.2)		
Haile et al. (2006)	< 1 yr	[49/86]	1.00 (reference)	[19/45]	1.00 (reference)
	≥ 1 yr	[146/214]	1.15 (0.75–1.74)	[109/132]	1.62 (0.90–2.92)
Brohet et al. (2007)	Never	[161/31 653]	1.00 (reference)	[78/11 958]	1.00 (reference)
	Ever	[436/15 912]	1.47 (1.3–1.19)	[171/5 657]	1.49 (0.08–2.70)
Total years of use					
Narod et al. (2002)	≤ 4 years	NG	1.10 (0.92–1.31)	NG	0.90 (0.67–1.20)
	5–9 years	NG	1.36 (1.11–1.69)	NG	0.82 (0.56–1.91)
	10–14 years	NG	1.27 (0.99–1.64)	NG	1.16 (0.75–1.78)
	15–30	NG	1.30 (0.91–1.87) ( <i>P</i> -trend = 0.006)	NG	1.35 (0.71–2.56) ( <i>P</i> -trend = 0.42)
Gronwald et al. (2006)	≤ 2 years	[21/14]	0.9 (0.5–1.5)	—	—
	> 2 years	[7/35]	0.8 (0.5–1.4)		
Haile et al. (2006)	1–4 years	[40/84]	0.97 (0.59–1.61)	[24/45]	1.16 (0.58–2.34)
	≥ 5 years	[102/128]	1.20 (0.78–1.85)	[84/83]	2.06 (1.08–3.94) ( <i>p</i> -trend = 0.008)
Brohet et al. (2007)	1–3 years	[141/6 677]	1.36 (0.99–1.88)	[72/3 002]	1.23 (0.64–2.35)
	4–8 years	[146/5 354]	1.51 (1.10–2.08)	[57/1 636]	2.27 (1.10–4.65)
	≥ 9 years	[118/2 208]	1.63 (1.17–2.29)	[36/678]	1.47 (0.66–3.28)
Years of use before first full-term pregnancy					
Haile et al. (2006)	< 1 year	[73/121]	1.00 (reference)	[30/83]	1.00 (reference)
	1–3 years	[38/73]	0.82 (0.54–1.24)	[25/36]	1.53 (0.86–2.74)
	≥ 4 years	[79/102]	0.91 (0.62–1.32)	[72/56]	3.46 (2.10–5.70) ( <i>p</i> -trend < 0.0001)
Brohet et al. (2007)	1–3 years	[122/5 951]	1.36 (0.94–1.95)	[48/2 265]	1.19 (0.62–2.30)
	> 4 years	[152/4 379]	1.49 (1.05–2.11)	[57/1 326]	2.58 (1.21–5.49)
Age at use					
Narod et al. (2002)	Any use before age 20	NG	1.14 (0.84–1.56)	—	
Haile et al. (2006)	Before age 30				
	< 1 year use	[51/89]	1.00 (reference)	[21/53]	1.00 (reference)
	1–3 years use	[6/25]	0.42 (0.20–0.85)	[5/13]	1.49 (0.51–4.34)
	≥ 4 years use	[134/183]	0.93 (0.64–1.35)	[101/109]	2.20 (1.26–3.85) ( <i>p</i> -trend = 0.008)
Brohet et al. (2007)	Any use				
	Before age 20	[176/7 677]	1.41 (0.99–2.01)	[53/2 153]	1.25 (0.57–2.74)
	Age 21–24	[147/4 553]	1.75 (1.24–2.46)	[71/2 133]	1.62 (0.80–3.31)